Anima Biotech, a pioneering leader in the field of small molecule mRNA drugs, is set to make a significant impact at the upcoming RNA Leaders Europe Congress in Basel, Switzerland. The company’s Vice President of Business Development, Gal Gur, Ph.D., will be participating in two roundtable sessions and giving a presentation on the innovative use of AI in mRNA biology.
During the congress, Dr. Gur will share her insights on target selection in the mRNA biology space, drawing from her experience at Anima Biotech. The sessions and presentation will focus on how Anima’s mRNA Lightning platform leverages AI to visualize the complete mRNA life cycle and decode mRNA biology underlying disease phenotypes. This technology has applications in drug and target discovery, mRNA vaccine optimization, and RNA-based drug optimization, with real-world examples in oncology and immunology.
The RNA Leaders Europe Congress program will cover a wide range of topics related to RNA biology, providing a platform for key stakeholders to discuss new data, technologies, and collaborations. Anima Biotech’s participation underscores the company’s commitment to advancing the field of mRNA drugs and leveraging cutting-edge technologies to drive innovation.
With strategic collaborations with industry giants like Lilly, Takeda, and Abbvie, Anima Biotech is at the forefront of revolutionizing the way we approach mRNA biology. The company’s proprietary visualization technologies and AI-driven approach have already generated significant interest and validation in the scientific community, with multiple patents, publications, and collaborations to their name.
For more information about Anima Biotech and their groundbreaking work in the field of mRNA drugs, visit their website at https://www.animabiotech.com. Stay updated on their latest developments by following them on LinkedIn and X at @AnimaBiotech.